Canada Human Fibrinogen Concentrates Market Size, Share and Trends 2026 to 2035
Canada Human Fibrinogen Concentrates Market (By Product: Fibryga, RiaSTAP, Others; By Application: Congenital Fibrinogen Deficiency, Acquired Fibrinogen Deficiency & Surgical Procedures, Others; By End User: Hospitals & ASCs, Specialty Clinics, Others) - Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2026 to 2035
Get a Sample
Table Of Content
What is the Canada Human Fibrinogen Concentrates Market Size?
The Canada human fibrinogen concentrates market size was calculated at USD 159.6 million in 2025 and is predicted to increase from USD 171.6 million in 2026 to approximately USD 329.39 million by 2035, expanding at a CAGR of 7.51% from 2026 to 2035.The market is driven by a strong public healthcare system, increasing awareness of rare bleeding disorders, and growing use of human fibrinogen concentrates in critical care and perioperative management.
Market Highlights
- By product, the RiaSTAP segment dominated the Canada human fibrinogen concentrates market with the largest share in 2025.
- By product, the Fibryga segment is expected to grow at the fastest CAGR in the market between 2026 and 2035.
- By application, the congenital fibrinogen deficiency segment held the largest market share in 2025.
- By application, the acquired fibrinogen deficiency & surgical procedures segment is expected to grow at the fastest CAGR in the market between 2026 and 2035.
- By end-user, the hospitals & ASCs segment dominated the market with the largest share in 2025.
- By end-user, the specialty clinics segment is expected to grow at the fastest CAGR in the market between 2026 and 2035.
Market Overview
The Canada human fibrinogen concentrates market comprises plasma derived fibrinogen products used to rapidly restore fibrinogen levels in patients with congenital or acquired bleeding disorders, trauma, and surgical bleeding, offering a standardized and safer alternative to traditional blood products. Fibrinogen concentrates provide advantages such as precise dosing, reduced risk of viral transmission, improved safety profiles, and better logistical handling compared with cryoprecipitate, which enhances clinical outcomes in emergency and surgical settings. The market is growing due to increasing prevalence and diagnosis of bleeding disorders, expanded clinical use in trauma and perioperative care, and rising clinician awareness of advanced hemostatic therapies.
Key Technological Shift in the Canada Human Fibrinogen Concentrates Market
Technological shifts are significantly influencing the market by enhancing product safety, efficacy, and reliability. Advances in plasma fractionation, purification, and viral inactivation technologies are reducing the risk of pathogen transmission, while improved chromatographic methods and lyophilization increase yield, consistency, and shelf life. These innovations, coupled with better quality control, batch traceability, and regulatory compliance, are strengthening clinical confidence and expanding the adoption of fibrinogen concentrates across hospitals and surgical centers. As a result, technology is driving market growth and positioning fibrinogen concentrates as a preferred hemostatic therapy in Canada.
Country-Level Analysis
- Toronto : Tronto represents a well-established market for human fibrinogen concentrates due to its concentration of large tertiary hospitals and specialized trauma and surgical care facilities. The advanced healthcare infrastructure of the area supports high usage in complex surgeries, emergency care, and hematology treatments. Strong clinical expertise, adherence to patient blood management protocols, and centralized procurement with established distribution networks further drive preference for fibrinogen concentrates over traditional blood products.
- East York :East York plays a significant role in the Canada human fibrinogen concentrates market through its integration with Toronto's broader healthcare system and access to regional hospitals. Usage is driven by routine surgeries, emergency care, and referrals from surrounding areas, while standardized treatment protocols support consistent adoption. The presence of community-based healthcare facilities further reinforces stable, long-term demand in this sub-regional market.
- Other Areas of Canada: Other areas of Canada contribute to the market through provincial healthcare systems and regional referral hospitals. British Columbia and Alberta show stable demand driven by trauma care, orthopedic surgeries, and cardiovascular procedures, while Quebec benefits from large academic hospitals and strong adoption of evidence-based transfusion practices. Atlantic Canada and the Prairie provinces exhibit moderate but consistent demand, mainly for emergency care and surgical interventions, whereas Northern and remote regions rely on centralized procurement and distribution to ensure timely access. Collectively, these regions support national market stability through steady institutional utilization rather than high-volume growth
Major Trends in the Canada Human Fibrinogen Concentrates Market
- Shift Toward Targeted Coagulation Therapy: Hospitals and clinicians are increasingly preferring fibrinogen concentrates over broad blood component transfusions to provide targeted, efficient hemostatic support and reduce transfusion‑related risks.
- Rising Use in Trauma and Surgical Settings: There is growing adoption of fibrinogen concentrates in trauma care, cardiac surgery, and other perioperative applications due to benefits like
standardized dosing and rapid reconstitution, which support better patient outcomes. - Stronger Clinical Evidence and Physician Adoption: Expanding clinical research and evidence supporting the safety and effectiveness of fibrinogen concentrates are encouraging broader acceptance among physicians and inclusion in patient blood management protocols.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 159.6Million |
| Market Size in 2026 | USD 171.6 Million |
| Market Size by 2035 | USD 329.39Million |
| Market Growth Rate from 2026 to 2035 | CAGR of 7.51% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Product, Application, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Segment Insights
Product Insights
Why Did the RiaSTAP Segment Dominate the Canada Human Fibrinogen Concentrates Market?
The RiaSTAP segment dominated the market in 2025 due to its long-term clinical application use and strong familiarity with physicians. It is widely recognized for effectively managing congenital fibrinogen deficiency, particularly during acute bleeding and surgical procedures. The proven safety profile and predictability of the therapeutic outcomes of the product have helped in strengthening clinical confidence in large hospitals in Canada. It is also well integrated into hospital formularies and emergency care plans, which also contribute to its high level of adoption. Additionally, RiaSTAP offers greater ease of use in critical care settings thanks to standardized dosing and treatment guidelines, which collectively help maintain its leadership position in the Canadian market.
The Fibryga segment is expected to grow at the fastest rate over the forecasted period due to the rising awareness of newer-generation fibrinogen concentrates. Its benefits, including high purity, viral safety, and flexible dosing, along with emerging clinical evidence, are encouraging clinician adoption for inherited and acquired fibrinogen deficiencies. Approvals and growing hospital uptake are accelerating its integration into routine practice, while its effectiveness in perioperative and trauma-related bleeding management further supports segmental growth. As treatment protocols modernize, the use of Fibryga is projected to continue rising at a strong pace.
Application Insights
How Does the Congenital Fibrinogen Deficiency Segment Dominate the Canada Human Fibrinogen Concentrates Market?
The congenital fibrinogen deficiency segment dominated the market with the largest share in 2025 because these patients require regular and reliable fibrinogen replacement to prevent or control bleeding episodes. Fibrinogen concentrates offer standardized dosing, rapid reconstitution, and proven safety, making them the preferred choice over traditional blood products in acute and surgical settings. Strong clinical familiarity, integration into hospital formularies, and supportive treatment guidelines further reinforce adoption among physicians. Collectively, these factors ensure consistent demand and maintain the segment's leadership in the Canadian market.
The acquired fibrinogen deficiency & surgical procedures segment is expected to grow at the fastest CAGR between 2026 and 2035 due to increasing use in managing bleeding during complex surgeries, trauma care, and cardiovascular procedures. Fibrinogen concentrates provide rapid hemostatic control, standardized dosing, and a safer alternative to traditional blood components, making them highly suitable for perioperative and emergency settings. Rising awareness among clinicians, expanding clinical evidence, and integration into patient blood management programs are further driving adoption. As hospitals focus on improving surgical outcomes and reducing transfusion-related risks, demand for fibrinogen concentrates in this segment continues to rise steadily.
End User Insights
Why Did the Hospitals & ASCs Segment Dominate the Market?
The hospitals & ASCs segment dominated the Canada human fibrinogen concentrates market with the largest share in 2025, driven by the need for rapid fibrinogen replacement during emergency bleeding, trauma, and surgeries. High-volume usage is supported by specialized transfusion services and intensive care units. Hospitals also play a central role in managing congenital fibrinogen deficiency during acute episodes, and their strong purchasing power and established treatment protocols further reinforce their dominance.
Strong integration of fibrinogen concentrates into hospital formularies, treatment protocols, and patient blood management programs further reinforces their adoption. Additionally, the availability of advanced infrastructure and clinical expertise in these facilities ensures consistent usage, maintaining their leadership in the market.
The specialty clinics segment is expected to expand at the fastest CAGR in the upcoming period due to the decentralization of care for rare bleeding disorders, allowing more treatments to be administered in outpatient and home-care settings. Clinics focused on hemophilia and coagulation disorders are increasingly adopting fibrinogen concentrates for individualized patient management. Improved home-care coordination and patient preference for less acute care environments are further supporting safe and convenient use outside hospitals. Collectively, these factors are driving steady demand and rapid growth for the specialty clinics segment.
Canada Human Fibrinogen Concentrates Market Value Chain Analysis
Who are the Major Players in the Canada Human Fibrinogen Concentrates Market?
The major players in the canada human fibrinogen concentrates market include CSL Behring LLC, Octapharma AG, LFB Group, Grifols, S.A., Baxter International Inc., Shanghai RAAS Blood Products Co., Ltd.,Hualan Biological Engineering Inc., Kedrion Biopharm, Biotest AG, Green Cross Corporation (GC Pharma), Jiangxi Boya Bio‑Pharmaceutical Co., Ltd., Sanquin Blood Supply Foundation
Recent Developments
- In February 2025, the National Advisory Committee on Blood and Blood Products confirmed that two fibrinogen concentrates are available in Canada: RiaSTAP (CSL Behring) and FIBRYGA (Octapharma). Both are approved for treating acute bleeding and perioperative prophylaxis in adults and children with congenital afibrinogenemia and hypofibrinogenemia, while FIBRYGA is also indicated for managing severe acquired fibrinogen deficiency during surgery. Their use in acquired hypofibrinogenemia is supported by clinical studies, including a high-quality randomized trial in cardiovascular surgery patients (Source: https://nacblood.ca)
Segments Covered in the Report
By Product
- Fibryga
- RiaSTAP
- Others
By Application
- Congenital Fibrinogen Deficiency
- Acquired Fibrinogen Deficiency & Surgical Procedures
- Others
By End User
- Hospitals & ASCs
- Specialty Clinics
- Others